Investor Relations
Corporate Profile
We are a clinical stage biopharmaceutical company focused on delivering transformational medicines to patients with high unmet medical need. Our current focus is on advancing our lead program AKR-001 to provide a powerful new treatment for patients with NASH, a disease for which there are currently no marketed therapies.
Copyright West LLC. Minimum 15 minutes delayed.
January 13, 2020
Akero Therapeutics Expands Phase 2a Trial in NASH to Include Cohort of Cirrhotic Patients
SAN FRANCISCO , Jan. 13, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-st...
January 8, 2020
Akero Therapeutics To Present At The 2020 J.P. Morgan Healthcare Conference
SAN FRANCISCO , Jan. 8, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-sta...
December 16, 2019
Akero Therapeutics Completes Enrollment in Phase 2a Study in NASH
SAN FRANCISCO , Dec. 16, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-s...
November 13, 2019
Akero Therapeutics to Present at the Jefferies 2019 London Healthcare Conference
SAN FRANCISCO , Nov. 13, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-s...
November 12, 2019
Akero Therapeutics Reports Recent Highlights and Third Quarter 2019 Financial Results
SAN FRANCISCO , Nov. 12, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-s...
November 11, 2019
Akero Chief Development Officer Kitty Yale Named to 2019 Fierce Pharma “Fiercest Women in Life Sciences”
Akero Therapeutics is thrilled to announce that its chief development officer Kitty Yale has been re...